2026-04-05 18:58:02

Breaking: Life Biosciences has initiated the first human clinical trial for a treatment based on partial genetic reprogramming, a method that aims to restore the function of aging cells without erasing their identity.

The candidate, ER 100, has been approved by the FDA and is already being tested on patients with open-angle glaucoma and NAION.
The FDA has authorized Life Biosciences to begin a Phase 1 human trial of ER 100, a treatment based on partial genetic reprogramming.

View Original

GateUser-05fb065f

2026-04-05 17:05:53

JUST IN: Life Biosciences has initiated the first human clinical trial of a therapy based on partial epigenetic reprogramming, an approach that seeks to restore the function of aging cells without erasing their identity.
The candidate, ER 100, has been approved by the FDA and is already being tested in patients with open angle glaucoma and NAION (non invasive glaucoma).
The FDA has authorized Life Biosciences to begin a Phase 1 human trial of ER 100, a partial epigenetic reprogramming therapy.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes